Y Intercept Hong Kong Ltd Sells 17,700 Shares of Enhabit, Inc. (NYSE:EHAB)

Y Intercept Hong Kong Ltd lessened its stake in Enhabit, Inc. (NYSE:EHAB) by 31.0% during the fourth quarter, Holdings Channel reports. The firm owned 39,314 shares of the company’s stock after selling 17,700 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Enhabit were worth $307,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of EHAB. Jane Street Group LLC boosted its holdings in Enhabit by 514.3% during the 3rd quarter. Jane Street Group LLC now owns 901,084 shares of the company’s stock worth $7,119,000 after acquiring an additional 754,395 shares during the last quarter. Paradice Investment Management LLC boosted its holdings in Enhabit by 12.8% during the fourth quarter. Paradice Investment Management LLC now owns 1,780,113 shares of the company’s stock worth $13,903,000 after purchasing an additional 201,997 shares during the last quarter. Systematic Financial Management LP grew its position in Enhabit by 12.2% in the 3rd quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock worth $14,522,000 after purchasing an additional 199,235 shares in the last quarter. Bardin Hill Management Partners LP increased its stake in Enhabit by 927.4% in the 3rd quarter. Bardin Hill Management Partners LP now owns 174,304 shares of the company’s stock valued at $1,377,000 after buying an additional 157,338 shares during the last quarter. Finally, West Tower Group LLC lifted its position in shares of Enhabit by 108.8% during the 3rd quarter. West Tower Group LLC now owns 285,142 shares of the company’s stock worth $2,253,000 after buying an additional 148,566 shares in the last quarter.

Insider Buying and Selling

In other Enhabit news, Director Stuart M. Mcguigan bought 15,000 shares of Enhabit stock in a transaction that occurred on Tuesday, December 10th. The stock was acquired at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares in the company, valued at $412,396.10. This represents a 47.15 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey Bolton purchased 4,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the acquisition, the director now owns 98,144 shares in the company, valued at approximately $852,871.36. This represents a 4.25 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by insiders.

Enhabit Stock Up 0.7 %

Enhabit stock opened at $8.49 on Wednesday. The firm has a market capitalization of $427.01 million, a price-to-earnings ratio of -3.66 and a beta of 1.83. The firm has a 50 day simple moving average of $8.14 and a 200 day simple moving average of $7.90. Enhabit, Inc. has a 1-year low of $6.85 and a 1-year high of $11.74. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Jefferies Financial Group raised Enhabit from a “hold” rating to a “buy” rating and increased their price target for the company from $8.25 to $9.50 in a research report on Monday, December 9th. Leerink Partners reiterated a “market perform” rating and set a $8.00 target price (down from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.75.

Enhabit Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.